<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819117</url>
  </required_header>
  <id_info>
    <org_study_id>CR05033IT</org_study_id>
    <nct_id>NCT00819117</nct_id>
  </id_info>
  <brief_title>Investigation of Transvenous Versus Epicardial Left Ventricular Stimulation Technique</brief_title>
  <acronym>INTREPID</acronym>
  <official_title>INvestigation of TRansvenous Versus EPIcarDial Left Ventricular Stimulation Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that epicardial and transvenous left ventricular
      leads are safe and effective for cardiac resynchronization therapy in heart failure patients
      implanted with a CRT device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a multicenter, prospective, randomized, parallel, open study designed
      to compare epicardial left ventricular pacing to transvenous left ventricular pacing for
      delivering cardiac resynchronization therapy.

      After a pre-implant baseline evaluation, patients will be randomized in a 1:1 fashion to one
      of two groups:

        -  Control group: resynchronization via a transvenous left ventricular lead (TVN CRT);

        -  Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT).

      All patients taking part in this study will undergo the implantation of a CRT device with or
      without ICD back-up (depending on the physician's decision), with right atrial and right
      ventricular transvenous leads.

      Patients will attend protocol scheduled visits before implant (pre-implant baseline
      evaluation), and post-implant: before hospital discharge, 6 weeks post-implant (optional
      visit), 3 months (optional visit), and 6 months after implant, time of study termination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy will be evaluated by comparing the pacing thresholds at 6 months between the two groups. The safety will be evaluated by comparing the survival from lead-related complications at 6 months between the two groups.</measure>
    <time_frame>6 months follow up after implant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Transvenous Lead (TVN CRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epicardial Lead (EPI CRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy implant</intervention_name>
    <description>Device implant with appropriate leads</description>
    <arm_group_label>Transvenous Lead (TVN CRT)</arm_group_label>
    <arm_group_label>Epicardial Lead (EPI CRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have an approved indication for implantation of an CRT device (ESC guidelines ,
             including any update);

          -  Have a stable pharmacological therapy.

        Exclusion Criteria:

          -  Have a contra-indication to general anesthesia;

          -  Have a scheduled cardiac surgery;

          -  Have had a recent myocardial infarction, unstable angina or cardiac revascularization
             (PTCA or CABG) within 1 month of enrollment;

          -  Have a life expectancy of less than 6 months;

          -  Are unable to provide informed consent;

          -  Are unable to comply with the follow-up schedule and tests;

          -  Are minor (age below 18 years);

          -  Are pregnant or are planning for pregnancy in the next 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Grazia Bongiorni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Cisanello, Pisa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Cisanello</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Osperaliera Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Angelo Rivetti, Country Manager</name_title>
    <organization>St.Jude Medical Italia Spa</organization>
  </responsible_party>
  <keyword>Epicardial leads</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

